HLX43 dose 2: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving HLX43 dose 2

• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
  NCT07269782 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
  NCT06848699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
  NCT07106892 · Phase: Phase 2 · Ages: 18 Days to 75 Days · Sex: All (male and female) · 2 locations

Common questions

How many recruiting trials involve HLX43 dose 2?

4 recruiting trials across 6 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.